Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Osiris Therapeutics, Inc.

http://www.osiris.com

Latest From Osiris Therapeutics, Inc.

Novartis Puts Down $50m For Mesoblast COVID-19 Cell Therapy

The Australian company's off-the-shelf cell therapy fell foul of the US FDA for graft-versus-host disease recently but Novartis is backing remestemcel-L as a potential treatment for acute respiratory distress syndrome.

Coronavirus COVID-19 Deals

Keeping Track: Disappointment For Mesoblast And Aquestive; Opdivo/Yervoy Add Mesothelioma Claim; Pediatric Approvals

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Pediatrics

US FDA Approval Activity Could Cool Down In September

With just 10 user fee goal dates coming up, September could be break from the fast pace of FDA decisions over the summer.

US FDA Performance Tracker Drug Review

The Greatest US FDA Advisory Committees: A Look Back At Tumult And Turning Points

With two landmark advisory committee meetings coming up, the Pink Sheet reflects on some of the most memorable panel meetings over the last 20 years.

Advisory Committees FDA
See All

Company Information

UsernamePublicRestriction

Register